ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Cincinnati, OH, USA:

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Cincinnati, Ohio, United States and 227 other locations

cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...

Enrolling
Mucosal Melanoma
Melanoma
Drug: Phase 1b: APG-115+pembrolizumab

Phase 1, Phase 2

Ascentage Pharma Group
Ascentage Pharma Group

Cincinnati, Ohio, United States and 20 other locations

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Cincinnati, Ohio, United States and 65 other locations

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC...

Enrolling
Melanoma
Drug: nivolumab+rHuPH20
Drug: relatlimab+nivolumab

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Edgewood, Kentucky, United States and 36 other locations

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma...

Enrolling
Metastatic Melanoma
Unresectable Melanoma
Biological: IOV-4001

Phase 1, Phase 2

Iovance Biotherapeutics

Cincinnati, Ohio, United States and 8 other locations

combined with nivolumab in patients with unresectable or metastatic melanoma. A separate open-label cohort of adults with new, progressive b...

Active, not recruiting
Unresectable or Metastatic Melanoma
Progressive Brain Metastasis
Drug: Placebo in combination with nivolumab
Drug: HBI-8000 in combination with nivolumab

Phase 3

HUYABIO

Edgewood, Kentucky, United States and 138 other locations

placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or pl...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Cincinnati, Ohio, United States and 158 other locations

(GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other so...

Enrolling
Metastatic Uveal Melanoma
Cutaneous Melanoma
Drug: IDE196
Drug: Binimetinib

Phase 1, Phase 2

Ideaya Biosciences

Cincinnati, Ohio, United States and 13 other locations

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects...

Enrolling
Non-melanoma Skin Cancer
Melanoma (Skin)
Biological: RP1
Biological: nivolumab

Phase 2

Replimune

Cincinnati, Ohio, United States and 52 other locations

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

Enrolling
Melanoma
Non Small Cell Lung Cancer
Biological: PD-1 inhibitor
Biological: CAB-ROR2-ADC

Phase 1, Phase 2

BioAtla

Cincinnati, Ohio, United States and 65 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems